Invion Limited
Research Invion Limited (IVX.AX) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerIVX.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyAUD
- Financial periodFY2025
- Net income-AUD 8.81M
- Free cash flow-AUD 2.97M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 8.81M | -AUD 2.97M | n/a | -0.12 | AUD 850.37K | n/a | AUD 8.25M |
| FY2024 | AUD 3.69M | -AUD 5.63M | -AUD 3.30M | 100.0% | -0.09 | AUD 783.53K | n/a | AUD 14.44M |
| FY2023 | AUD 4.10M | -AUD 1.61M | -AUD 4.39M | 100.0% | -0.03 | AUD 4.08M | n/a | AUD 18.40M |
| FY2022 | AUD 3.29M | -AUD 2.24M | -AUD 8.36M | 100.0% | -0.04 | AUD 8.47M | n/a | AUD 19.58M |
| FY2021 | AUD 2.33M | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Invion Limited do?
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus.